Advertisement
Published in:
15-08-2024 | Glioma in Children | Review
Advances in the Treatment of Pediatric Low-Grade Gliomas
Published in: Current Neurology and Neuroscience Reports | Issue 10/2024
Login to get accessPlease log in to get access to this content
Literature
1.
go back to reference Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Suppl 5):v1–100. https://doi.org/10.1093/neuonc/noz150.CrossRefPubMedPubMedCentral
Ostrom QT, Cioffi G, Gittleman H, Patil N, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012–2016. Neuro Oncol. 2019;21(Suppl 5):v1–100. https://doi.org/10.1093/neuonc/noz150.CrossRefPubMedPubMedCentral
2.
go back to reference Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106.CrossRefPubMedPubMedCentral
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23(8):1231–51. https://doi.org/10.1093/neuonc/noab106.CrossRefPubMedPubMedCentral
3.
go back to reference de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31(1):21–7. https://doi.org/10.1097/MOP.0000000000000717.CrossRefPubMedPubMedCentral
de Blank P, Bandopadhayay P, Haas-Kogan D, Fouladi M, Fangusaro J. Management of pediatric low-grade glioma. Curr Opin Pediatr. 2019;31(1):21–7. https://doi.org/10.1097/MOP.0000000000000717.CrossRefPubMedPubMedCentral
4.
go back to reference Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8(1):30. https://doi.org/10.1186/s40478-020-00902-z.CrossRefPubMedPubMedCentral
Ryall S, Tabori U, Hawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8(1):30. https://doi.org/10.1186/s40478-020-00902-z.CrossRefPubMedPubMedCentral
5.
go back to reference Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Glioma Nat Rev Dis Primers. 2024;10(1):33. https://doi.org/10.1038/s41572-024-00516-y.CrossRefPubMed
Weller M, Wen PY, Chang SM, Dirven L, Lim M, Monje M, Reifenberger G. Glioma Nat Rev Dis Primers. 2024;10(1):33. https://doi.org/10.1038/s41572-024-00516-y.CrossRefPubMed
6.
go back to reference Rousseau J, Bennett J, Lim-Fat MJ. Brain Tumors in Adolescents and Young Adults: A Review. Semin Neurol. 2023;43(6):909–28. https://doi.org/10.1055/s-0043-1776775.CrossRefPubMed
Rousseau J, Bennett J, Lim-Fat MJ. Brain Tumors in Adolescents and Young Adults: A Review. Semin Neurol. 2023;43(6):909–28. https://doi.org/10.1055/s-0043-1776775.CrossRefPubMed
7.
go back to reference Bale TA, Rosenblum MK. The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol. 2022;32(4): e13060. https://doi.org/10.1111/bpa.13060.CrossRefPubMedPubMedCentral
Bale TA, Rosenblum MK. The 2021 WHO Classification of Tumors of the Central Nervous System: An update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol. 2022;32(4): e13060. https://doi.org/10.1111/bpa.13060.CrossRefPubMedPubMedCentral
8.
go back to reference Haizel-Cobbina J, Thakkar R, Richard K, Du L, Levine A, Bennett J, et al. Clinical and molecular features of disseminated pediatric low-grade glioma and glioneuronal tumors: a systematic review and survival analysis. Neurooncol Adv. 2022;4(1):vdac122. https://doi.org/10.1093/noajnl/vdac122.CrossRefPubMedPubMedCentral
Haizel-Cobbina J, Thakkar R, Richard K, Du L, Levine A, Bennett J, et al. Clinical and molecular features of disseminated pediatric low-grade glioma and glioneuronal tumors: a systematic review and survival analysis. Neurooncol Adv. 2022;4(1):vdac122. https://doi.org/10.1093/noajnl/vdac122.CrossRefPubMedPubMedCentral
9.
go back to reference Samples DC, Mulcahy Levy JM, Hankinson TC. Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management. Front Surg. 2022;9:884250. https://doi.org/10.3389/fsurg.2022.884250.CrossRefPubMedPubMedCentral
Samples DC, Mulcahy Levy JM, Hankinson TC. Neurosurgery for Optic Pathway Glioma: Optimizing Multidisciplinary Management. Front Surg. 2022;9:884250. https://doi.org/10.3389/fsurg.2022.884250.CrossRefPubMedPubMedCentral
10.
go back to reference Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery. 2011;68(6):1548–54; discussion 54–5. https://doi.org/10.1227/NEU.0b013e318214a66e
Wisoff JH, Sanford RA, Heier LA, Sposto R, Burger PC, Yates AJ, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery. 2011;68(6):1548–54; discussion 54–5. https://doi.org/10.1227/NEU.0b013e318214a66e
11.
go back to reference Manoharan N, Liu KX, Mueller S, Haas-Kogan DA, Bandopadhayay P. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023;36:100857. https://doi.org/10.1016/j.neo.2022.100857.CrossRefPubMed
Manoharan N, Liu KX, Mueller S, Haas-Kogan DA, Bandopadhayay P. Pediatric low-grade glioma: Targeted therapeutics and clinical trials in the molecular era. Neoplasia. 2023;36:100857. https://doi.org/10.1016/j.neo.2022.100857.CrossRefPubMed
12.
go back to reference Strauss I, Gabay S, Roth J. Laser interstitial thermal therapy (LITT) for pediatric low-grade glioma-case presentations and lessons learned. Childs Nerv Syst. 2024https://doi.org/10.1007/s00381-024-06419-3
Strauss I, Gabay S, Roth J. Laser interstitial thermal therapy (LITT) for pediatric low-grade glioma-case presentations and lessons learned. Childs Nerv Syst. 2024https://doi.org/10.1007/s00381-024-06419-3
13.
go back to reference Lassaletta A, Zapotocky M, Bouffet E. Chemotherapy in pediatric low-grade gliomas (PLGG). Childs Nerv Syst. 2024https://doi.org/10.1007/s00381-024-06458-w
Lassaletta A, Zapotocky M, Bouffet E. Chemotherapy in pediatric low-grade gliomas (PLGG). Childs Nerv Syst. 2024https://doi.org/10.1007/s00381-024-06458-w
14.
go back to reference Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio P, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report. Eur J Cancer. 2017;81:206–25. https://doi.org/10.1016/j.ejca.2017.04.019.CrossRefPubMedPubMedCentral
Gnekow AK, Walker DA, Kandels D, Picton S, Giorgio P, Grill J, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (</=16 years) low grade glioma - A final report. Eur J Cancer. 2017;81:206–25. https://doi.org/10.1016/j.ejca.2017.04.019.CrossRefPubMedPubMedCentral
15.
go back to reference Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358–63. https://doi.org/10.1200/JCO.2011.34.5843.CrossRefPubMed
Bouffet E, Jakacki R, Goldman S, Hargrave D, Hawkins C, Shroff M, et al. Phase II study of weekly vinblastine in recurrent or refractory pediatric low-grade glioma. J Clin Oncol. 2012;30(12):1358–63. https://doi.org/10.1200/JCO.2011.34.5843.CrossRefPubMed
16.
go back to reference Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641–7. https://doi.org/10.1200/JCO.2011.36.6054.CrossRefPubMedPubMedCentral
Ater JL, Zhou T, Holmes E, Mazewski CM, Booth TN, Freyer DR, et al. Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children’s Oncology Group. J Clin Oncol. 2012;30(21):2641–7. https://doi.org/10.1200/JCO.2011.36.6054.CrossRefPubMedPubMedCentral
17.
go back to reference Cappellano AM, Petrilli AS, da Silva NS, Silva FA, Paiva PM, Cavalheiro S, Bouffet E. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol. 2015;121(2):405–12. https://doi.org/10.1007/s11060-014-1652-6.CrossRefPubMed
Cappellano AM, Petrilli AS, da Silva NS, Silva FA, Paiva PM, Cavalheiro S, Bouffet E. Single agent vinorelbine in pediatric patients with progressive optic pathway glioma. J Neurooncol. 2015;121(2):405–12. https://doi.org/10.1007/s11060-014-1652-6.CrossRefPubMed
18.
go back to reference Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20(20):4209–16. https://doi.org/10.1200/JCO.2002.08.087.CrossRefPubMed
Massimino M, Spreafico F, Cefalo G, Riccardi R, Tesoro-Tess JD, Gandola L, et al. High response rate to cisplatin/etoposide regimen in childhood low-grade glioma. J Clin Oncol. 2002;20(20):4209–16. https://doi.org/10.1200/JCO.2002.08.087.CrossRefPubMed
19.
go back to reference Dodgshun AJ, SantaCruz N, Hwang J, Ramkissoon SH, Malkin H, Bergthold G, et al. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016;128(2):293–302. https://doi.org/10.1007/s11060-016-2109-x.CrossRefPubMed
Dodgshun AJ, SantaCruz N, Hwang J, Ramkissoon SH, Malkin H, Bergthold G, et al. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. J Neurooncol. 2016;128(2):293–302. https://doi.org/10.1007/s11060-016-2109-x.CrossRefPubMed
20.
go back to reference Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2021;23(10):1777–88. https://doi.org/10.1093/neuonc/noab047.CrossRefPubMedPubMedCentral
Fangusaro J, Onar-Thomas A, Poussaint TY, Wu S, Ligon AH, Lindeman N, et al. A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro Oncol. 2021;23(10):1777–88. https://doi.org/10.1093/neuonc/noab047.CrossRefPubMedPubMedCentral
21.
go back to reference Perreault S, Larouche V, Tabori U, Hawkins C, Lippé S, Ellezam B, et al. SYST-04. TRAM-01: a phase 2 study of trametinib for patients with pediatric glioma with activation of the mapk/erk pathway. Neuro-Oncology Advances. 2021;3(Supplement_4):9. https://doi.org/10.1093/noajnl/vdab112.032
Perreault S, Larouche V, Tabori U, Hawkins C, Lippé S, Ellezam B, et al. SYST-04. TRAM-01: a phase 2 study of trametinib for patients with pediatric glioma with activation of the mapk/erk pathway. Neuro-Oncology Advances. 2021;3(Supplement_4):9. https://doi.org/10.1093/noajnl/vdab112.032
22.
go back to reference Robison N, Pauly J, Malvar J, Gardner S, Allen J, Margol A, et al. LTBK-04. Late breaking abstract: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study. Neuro-Oncology. 2022;24(Supplement_1):i191-i2. https://doi.org/10.1093/neuonc/noac079.716
Robison N, Pauly J, Malvar J, Gardner S, Allen J, Margol A, et al. LTBK-04. Late breaking abstract: MEK162 (binimetinib) in children with progressive or recurrent low-grade glioma: a multi-institutional phase II and target validation study. Neuro-Oncology. 2022;24(Supplement_1):i191-i2. https://doi.org/10.1093/neuonc/noac079.716
23.
go back to reference Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, et al. Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: pacific pediatric neuro-oncology consortium study (PNOC-002). Oncotarget. 2020;11(21):1942–52. https://doi.org/10.18632/oncotarget.27600.CrossRefPubMedPubMedCentral
Nicolaides T, Nazemi KJ, Crawford J, Kilburn L, Minturn J, Gajjar A, et al. Phase I study of vemurafenib in children with recurrent or progressive BRAF(V600E) mutant brain tumors: pacific pediatric neuro-oncology consortium study (PNOC-002). Oncotarget. 2020;11(21):1942–52. https://doi.org/10.18632/oncotarget.27600.CrossRefPubMedPubMedCentral
24.
go back to reference Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, et al. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res. 2019;25(24):7303–11. https://doi.org/10.1158/1078-0432.CCR-19-2177.CrossRefPubMed
Hargrave DR, Bouffet E, Tabori U, Broniscer A, Cohen KJ, Hansford JR, et al. Efficacy and Safety of Dabrafenib in Pediatric Patients with BRAF V600 Mutation-Positive Relapsed or Refractory Low-Grade Glioma: Results from a Phase I/IIa Study. Clin Cancer Res. 2019;25(24):7303–11. https://doi.org/10.1158/1078-0432.CCR-19-2177.CrossRefPubMed
25.
go back to reference Bouffet E, Hansford JR, Garre ML, Hara J, Plant-Fox A, Aerts I, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023;389(12):1108–20. https://doi.org/10.1056/NEJMoa2303815.CrossRefPubMed
Bouffet E, Hansford JR, Garre ML, Hara J, Plant-Fox A, Aerts I, et al. Dabrafenib plus Trametinib in Pediatric Glioma with BRAF V600 Mutations. N Engl J Med. 2023;389(12):1108–20. https://doi.org/10.1056/NEJMoa2303815.CrossRefPubMed
26.
go back to reference Wright K, Kline C, Abdelbaki M, Ebb D, Sayour E, Elster J, et al. CTNI-53. PNOC014: phase ib study results of day101(TOVORAFENIB) for children with low-grade gliomas (LGGS) and other RAS/RAF/MEK/ERK pathway-activated Tumors. Neuro-Oncol. 2022;24(Supplement_7):vii84-vii. https://doi.org/10.1093/neuonc/noac209.318.
Wright K, Kline C, Abdelbaki M, Ebb D, Sayour E, Elster J, et al. CTNI-53. PNOC014: phase ib study results of day101(TOVORAFENIB) for children with low-grade gliomas (LGGS) and other RAS/RAF/MEK/ERK pathway-activated Tumors. Neuro-Oncol. 2022;24(Supplement_7):vii84-vii. https://doi.org/10.1093/neuonc/noac209.318.
27.
go back to reference Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30(1):207–17. https://doi.org/10.1038/s41591-023-02668-y.CrossRefPubMed
Kilburn LB, Khuong-Quang DA, Hansford JR, Landi D, van der Lugt J, Leary SES, et al. The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial. Nat Med. 2024;30(1):207–17. https://doi.org/10.1038/s41591-023-02668-y.CrossRefPubMed
28.
go back to reference van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martinez O, et al. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer. 2024;24(1):147. https://doi.org/10.1186/s12885-024-11820-x.CrossRefPubMedPubMedCentral
van Tilburg CM, Kilburn LB, Perreault S, Schmidt R, Azizi AA, Cruz-Martinez O, et al. LOGGIC/FIREFLY-2: a phase 3, randomized trial of tovorafenib vs. chemotherapy in pediatric and young adult patients with newly diagnosed low-grade glioma harboring an activating RAF alteration. BMC Cancer. 2024;24(1):147. https://doi.org/10.1186/s12885-024-11820-x.CrossRefPubMedPubMedCentral
29.
go back to reference Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020;22(10):1527–35. https://doi.org/10.1093/neuonc/noaa071.CrossRefPubMedPubMedCentral
Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman S, et al. A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. Neuro Oncol. 2020;22(10):1527–35. https://doi.org/10.1093/neuonc/noaa071.CrossRefPubMedPubMedCentral
30.
go back to reference Wright KD, Yao X, London WB, Kao PC, Gore L, Hunger S, et al. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021;68(2):e28787. https://doi.org/10.1002/pbc.28787.CrossRefPubMed
Wright KD, Yao X, London WB, Kao PC, Gore L, Hunger S, et al. A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. Pediatr Blood Cancer. 2021;68(2):e28787. https://doi.org/10.1002/pbc.28787.CrossRefPubMed
31.
go back to reference Haas-Kogan DA, Aboian MS, Minturn JE, Leary SES, Abdelbaki MS, Goldman S, et al. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024;42(4):441–51. https://doi.org/10.1200/JCO.23.01838.CrossRefPubMed
Haas-Kogan DA, Aboian MS, Minturn JE, Leary SES, Abdelbaki MS, Goldman S, et al. Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial. J Clin Oncol. 2024;42(4):441–51. https://doi.org/10.1200/JCO.23.01838.CrossRefPubMed
32.
go back to reference Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D, et al. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precis Oncol. 2020;4. https://doi.org/10.1200/PO.19.00298.
Nobre L, Zapotocky M, Ramaswamy V, Ryall S, Bennett J, Alderete D, et al. Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precis Oncol. 2020;4. https://doi.org/10.1200/PO.19.00298.
Metadata
- Title
- Advances in the Treatment of Pediatric Low-Grade Gliomas
- Authors
-
Inci Yaman Bajin
Eric Bouffet
- Publication date
- 15-08-2024
- Publisher
- Springer US
- Keywords
- Glioma in Children
Glioma
Disease of the Nervous System in Children
Glioma
Glioma
Cancer Therapy
Targeted Therapy
Pediatric Neurosurgery
Neurofibromatosis Type 1
Molecular Genetics
Genetic Testing
Astrocytoma
Astrocytoma
Astrocytoma
Pediatric Surgery
Distal Radioulnar Joint Arthrosis
Everolimus
Cytostatic Therapy - Published in
-
Current Neurology and Neuroscience Reports
/ Issue 10/2024
Print ISSN: 1528-4042
Electronic ISSN: 1534-6293 - DOI
- https://doi.org/10.1007/s11910-024-01369-4
Image Credits
Young boy receiving chemotherapy/© FatCamera / Getty Images / iStock (symbolic image with model), Stylized collage of women/© (M) VictoriaBar / Getty Images / iStock, Genetic code/© Springer Healthcare, Aplastic Anemia/© Springer Healthcare IME